They'll be heading to Phoenix with their families for a few days to meet players, participate in warmups, tour the clubhouse ...

They'll be heading to Phoenix with their families for a few days to meet players, participate in warmups, tour the clubhouse and throw out the first pitch at a spring training game.

of andecaliximab in patients with fibrodysplasia ossificans progressiva (FOP). The dosing milestone for andecaliximab, āshibio’s lead product candidate, marks advancement of the company’s first ...

Fintel reports that on January 21, 2025, Cantor Fitzgerald downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) from Overweight to Neutral. Analyst Price Forecast Suggests 310.14% Upside As ...

It is being developed by velocimmune technology platform. The drug candidate was under development for the treatment of fibrodysplasia ossificans progressiva, administered through subcutaneous and ...

In a mouse model of fibrodysplasia ossificans progressiva (FOP)-a genetic condition causing abnormal bone growth in soft tissues-DDR2 deficiency markedly reduced heterotopic ossification.

Again, there is little scientific data to support this method of treatment. One of the unusual complications of a muscle contusion is called myositis ossificans. This unusual complication tends to ...

The recent announcement that Renovos Biologics Ltd. received FDA Breakthrough Device designation for its synthetic nanoclay bone fusion gel, RENOVITE ® BMP-2, is the latest in a string of ...

The board of directors of the American Academy of Orthopaedic Surgeons (AAOS) has approved a new position statement that urges orthopedic surgeons and patients to be fully aware of the risks and ...